drugset / Trial / NCT00359840

A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor

NCT00359840

Phase 2 Completed 120 enrolled Kyowa Kirin, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the clinical effective dose of KRN321 administered with once triweekly schedule.

Timeline

Start
2006-07
Primary completion
2007-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Darbepoetin alfa Protein / enzyme biologic

Indications